TP53 and breast cancer: For metastatic BC, we discovered that mutations in RB1 and RICTOR were significantly associated with worse clinical outcomes for both K-MASTER and MSK-IMPACT YBC patients, whereas TP53 and U2AF1 mutations conferred survival disadvantages in OBC patients from both cohorts.